MA40993A - Dérivés de 4-oxo-3,4-dihydro-1,2,3-benzotriazine comme modulateurs gpr139 - Google Patents

Dérivés de 4-oxo-3,4-dihydro-1,2,3-benzotriazine comme modulateurs gpr139

Info

Publication number
MA40993A
MA40993A MA040993A MA40993A MA40993A MA 40993 A MA40993 A MA 40993A MA 040993 A MA040993 A MA 040993A MA 40993 A MA40993 A MA 40993A MA 40993 A MA40993 A MA 40993A
Authority
MA
Morocco
Prior art keywords
gpr139
modulators
dihydro
oxo
compounds
Prior art date
Application number
MA040993A
Other languages
English (en)
Other versions
MA40993B1 (fr
Inventor
Stephen Hitchcock
Betty Lam
Holger Monenschein
Holly Reichard
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MA40993A publication Critical patent/MA40993A/fr
Publication of MA40993B1 publication Critical patent/MA40993B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un procédé permettant de traiter une maladie, un trouble ou un état pathologique associé à gpr139 à l'aide de composés de formule 1, lesquels composés sont des agonistes de gpr139, certains composés représentés par la formule 1, des compositions pharmaceutiques de ceux-ci, des procédés de fabrication desdits composés, et des intermédiaires de ceux-ci.
MA40993A 2014-11-20 2015-11-19 Dérivés de 4-oxo-3,4-dihydro-1,2,3-benzotriazine comme modulateurs gpr139 MA40993B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462082539P 2014-11-20 2014-11-20
US201562184729P 2015-06-25 2015-06-25
PCT/US2015/061607 WO2016081736A1 (fr) 2014-11-20 2015-11-19 4-oxo-3,4-dihydro-1,2,3-benzotriazines utilisées en tant que modulateurs de gpr139

Publications (2)

Publication Number Publication Date
MA40993A true MA40993A (fr) 2017-09-27
MA40993B1 MA40993B1 (fr) 2019-07-31

Family

ID=55022667

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40993A MA40993B1 (fr) 2014-11-20 2015-11-19 Dérivés de 4-oxo-3,4-dihydro-1,2,3-benzotriazine comme modulateurs gpr139

Country Status (40)

Country Link
US (5) US9556130B2 (fr)
EP (2) EP3536324B1 (fr)
JP (2) JP6637501B2 (fr)
KR (1) KR102582021B1 (fr)
CN (2) CN107108531B (fr)
AU (1) AU2015349866B2 (fr)
CA (1) CA2968242C (fr)
CL (1) CL2017001292A1 (fr)
CO (1) CO2017005959A2 (fr)
CR (1) CR20170275A (fr)
CY (2) CY1122613T1 (fr)
DK (2) DK3536324T3 (fr)
DO (1) DOP2017000120A (fr)
EA (1) EA033728B1 (fr)
EC (1) ECSP17038999A (fr)
ES (2) ES2897545T3 (fr)
GE (2) GEP20196961B (fr)
HR (2) HRP20191003T1 (fr)
HU (2) HUE044145T2 (fr)
IL (1) IL252311B (fr)
JO (1) JO3719B1 (fr)
LT (2) LT3536324T (fr)
MA (1) MA40993B1 (fr)
MD (1) MD3221298T2 (fr)
MX (1) MX378158B (fr)
MY (1) MY187423A (fr)
NZ (1) NZ732208A (fr)
PE (1) PE20170899A1 (fr)
PH (1) PH12017500920B1 (fr)
PL (2) PL3221298T3 (fr)
PT (2) PT3221298T (fr)
RS (2) RS59078B1 (fr)
SG (1) SG11201704002UA (fr)
SI (2) SI3536324T1 (fr)
SM (2) SMT201900355T1 (fr)
TN (1) TN2017000196A1 (fr)
TW (1) TWI684590B (fr)
UA (1) UA120375C2 (fr)
UY (1) UY36406A (fr)
WO (1) WO2016081736A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3719B1 (ar) 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139
WO2020081538A1 (fr) 2018-10-16 2020-04-23 The Scripps Research Institute Méthodes associées à des agents thérapeutiques opioïdes
WO2020097609A1 (fr) 2018-11-09 2020-05-14 Blackthorn Therapeutics, Inc. Modulateurs du récepteur gpr139
PL4031552T3 (pl) 2019-09-16 2025-03-17 Takeda Pharmaceutical Company Limited Pochodne azolowo-skondensowanych pirydazyn-3(2h)-onów
WO2021127459A1 (fr) * 2019-12-20 2021-06-24 Blackthorn Therapeutics, Inc. Modulateurs du récepteur gpr139
JP7697974B2 (ja) * 2020-05-08 2025-06-24 武田薬品工業株式会社 Ｇｐｒ１３９アゴニストの置換ベンゾトリアジノン代謝物
TW202227087A (zh) * 2020-09-21 2022-07-16 日商武田藥品工業股份有限公司 精神分裂症之治療
US11760788B2 (en) 2021-03-02 2023-09-19 Pathways Neuro Pharma, Inc. Neuroreceptor compositions and methods of use
WO2023165262A1 (fr) * 2022-03-01 2023-09-07 上海科技大学 Composé hétérocyclique contenant un thiéno-azote, composition pharmaceutique le comprenant, son procédé de préparation et son utilisation
US20250163065A1 (en) * 2022-03-01 2025-05-22 Shanghaitech University Pyrrolotriazinone compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof
CN117986183A (zh) * 2022-10-28 2024-05-07 浙江友宁生物医药科技有限公司 一种gpr139受体激动剂、其制备方法及其应用
WO2024102802A1 (fr) * 2022-11-11 2024-05-16 Takeda Pharmaceutical Company Limited Zélatriazine pour le traitement de la dépression
WO2025119351A1 (fr) * 2023-12-08 2025-06-12 深圳湾实验室 Agoniste de gpr139
WO2025162441A1 (fr) * 2024-02-02 2025-08-07 上海科技大学 Composés hétérocycliques fusionnés, leur procédé de préparation, compositions pharmaceutiques et leur utilisation
CN121159462A (zh) * 2025-11-19 2025-12-19 杭州市第七人民医院(杭州市心理危机研究与干预中心) 喹唑啉酮类化合物及其在制备神经系统疾病药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3794726A (en) * 1972-08-21 1974-02-26 Uniroyal Inc Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one
EP0799617A3 (fr) 1986-02-24 1997-11-12 Mitsui Petrochemical Industries, Ltd. Agent thérapeutique pour le traitement des maladies neurologiques
EP0315390B1 (fr) * 1987-11-04 1994-07-20 Beecham Group Plc Composés nouveaux de 4-oxobenzotriazine et 4-oxoquinazoline
WO2004108673A2 (fr) 2003-06-09 2004-12-16 Boehringer Ingelheim International Gmbh Inhibiteurs du papillomavirus
CA2533824A1 (fr) 2003-07-31 2005-02-10 Irm, Llc Composes bicycliques et compositions utilisees comme inhibiteurs pdf
FR2875805B1 (fr) 2004-09-27 2006-12-29 Genfit S A Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations
UY30048A1 (es) 2005-12-23 2007-07-31 Astrazeneca Ab Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
JP2010521513A (ja) * 2007-03-23 2010-06-24 エフ．ホフマン−ラ ロシュ アーゲー アザ−ピリドピリミジノン誘導体
US8642660B2 (en) * 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2011138265A2 (fr) 2010-05-03 2011-11-10 Evotec Ag Dérivés d'indole et d'indazole utilisés comme antagonistes du récepteur de l'orexine
US20140336216A1 (en) 2013-03-14 2014-11-13 Janssen Pharmaceutica Nv Physiological ligands for gpr139
JO3719B1 (ar) * 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139

Also Published As

Publication number Publication date
HUE044145T2 (hu) 2019-09-30
TWI684590B (zh) 2020-02-11
EP3221298A1 (fr) 2017-09-27
TW201625566A (zh) 2016-07-16
TN2017000196A1 (en) 2018-10-19
PH12017500920A1 (en) 2017-11-20
IL252311B (en) 2020-07-30
HUE057451T2 (hu) 2022-05-28
MD3221298T2 (ro) 2019-10-31
PT3221298T (pt) 2019-06-28
US10159677B2 (en) 2018-12-25
PE20170899A1 (es) 2017-07-12
HRP20212009T1 (hr) 2022-04-01
EA201791096A1 (ru) 2017-11-30
CN107108531B (zh) 2020-10-20
US20160145218A1 (en) 2016-05-26
JP6918088B2 (ja) 2021-08-11
GEAP201814515A (en) 2018-12-10
ES2897545T3 (es) 2022-03-01
US10561662B2 (en) 2020-02-18
LT3536324T (lt) 2021-12-10
KR20170084324A (ko) 2017-07-19
DK3221298T3 (da) 2019-06-24
CO2017005959A2 (es) 2017-10-20
CY1122613T1 (el) 2021-05-05
CN107108531A (zh) 2017-08-29
SMT202200142T1 (it) 2022-05-12
IL252311A0 (en) 2017-07-31
US20200129518A1 (en) 2020-04-30
WO2016081736A1 (fr) 2016-05-26
DOP2017000120A (es) 2017-06-15
KR102582021B1 (ko) 2023-09-22
MY187423A (en) 2021-09-22
US9770450B2 (en) 2017-09-26
CA2968242C (fr) 2022-11-08
RS59078B1 (sr) 2019-09-30
HRP20191003T1 (hr) 2019-08-23
US20190070187A1 (en) 2019-03-07
US20170348319A1 (en) 2017-12-07
LT3221298T (lt) 2019-08-12
UY36406A (es) 2016-06-30
CR20170275A (es) 2017-10-30
ES2734735T3 (es) 2019-12-11
NZ732208A (en) 2023-02-24
AU2015349866B2 (en) 2020-12-03
CY1124929T1 (el) 2023-01-05
CA2968242A1 (fr) 2016-05-26
EP3221298B1 (fr) 2019-04-03
PH12017500920B1 (en) 2017-11-20
ECSP17038999A (es) 2017-10-31
CL2017001292A1 (es) 2018-02-16
UA120375C2 (uk) 2019-11-25
EP3536324A1 (fr) 2019-09-11
BR112017010311A2 (pt) 2017-12-26
DK3536324T3 (da) 2021-10-25
CN112062730A (zh) 2020-12-11
US20170095480A1 (en) 2017-04-06
EA033728B1 (ru) 2019-11-20
JP2020063285A (ja) 2020-04-23
US9556130B2 (en) 2017-01-31
SG11201704002UA (en) 2017-06-29
GEP20196961B (en) 2019-03-25
PL3221298T3 (pl) 2019-10-31
MX2017006448A (es) 2017-09-12
EP3536324B1 (fr) 2021-10-06
US11173161B2 (en) 2021-11-16
JP2017535559A (ja) 2017-11-30
PT3536324T (pt) 2021-11-10
PL3536324T3 (pl) 2022-02-07
MA40993B1 (fr) 2019-07-31
CN112062730B (zh) 2023-09-29
MX378158B (es) 2025-03-10
JP6637501B2 (ja) 2020-01-29
AU2015349866A1 (en) 2017-06-15
JO3719B1 (ar) 2021-01-31
RS62563B1 (sr) 2021-12-31
SMT201900355T1 (it) 2019-07-11
SI3221298T1 (sl) 2019-10-30
SI3536324T1 (sl) 2021-12-31

Similar Documents

Publication Publication Date Title
MA40993B1 (fr) Dérivés de 4-oxo-3,4-dihydro-1,2,3-benzotriazine comme modulateurs gpr139
EA201650031A1 (ru) Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
MX388682B (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
EA201791002A1 (ru) Новые соединения, модулирующие fxr (nr1h4)
EA201692418A1 (ru) Замещенные индазольные соединения в качестве irak4 ингибиторов
EA201691514A1 (ru) Соединения
MA40302A1 (fr) Dérivés de carbazole
MX2021008094A (es) Metodos y composiciones para el tratamiento del cancer.
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
CL2020001589A1 (es) Proceso para la preparación de derivados de quinolina.
MA39171A1 (fr) Dérivés d'hydroxy formamide et leur utilisation
MA39335B1 (fr) Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone
NZ746906A (en) Oxaborole esters and uses thereof
AU2016380190A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
MX382175B (es) Composiciones de profármaco de monometilfumarato
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
MA39315A1 (fr) Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique
MA39337A1 (fr) Modulateurs de pyrazines de gpr6
PE20160860A1 (es) Derivados de etinil-imidazolidin-2,4-diona como moduladores de mglur 4
CL2017000484A1 (es) Compuestos de azetidiniloxifenilpirrolidina
EA202190271A1 (ru) Замещенные триазолохиноксалиновые производные
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов
MX367852B (es) Derivados de isotiazol como agonistas del gpr120 para el tratamiento de la diabetes tipo ii.
MA46307A1 (fr) Composition et procédés pour moduler l'expression du facteur b du complément
MA35887B1 (fr) Nouveaux dérivés morpholynyle utiles comme inhibiteurs de mogat-2